HCPLive

FDA Approves Ravicti for Urea Cycle Disorders

 
FDA Approves Ravicti for Urea Cycle DisordersFRIDAY, Feb. 1 (HealthDay News) -- Ravicti (glycerol phenylbutyrate) has been approved by the U.S. Food and Drug Administration to treat certain urea cycle disorders (UCDs) in people 2 years and older.

These inherited conditions involve a lack of enzymes that help the body remove ammonia from the blood. In people with UCDs, ammonia build-up can lead to coma, brain damage, or death, the FDA said Friday in a news release.

Ravicti is a liquid taken three times daily with meals. It's been approved for people whose disorders cannot be managed by a protein-restricted diet or amino acid supplements alone, the agency said.

Ravicti was compared to another UCD drug in a clinical study involving 44 adults. The most common side effects of the new drug were diarrhea, flatulence, and headache.

Ravicti is marketed by Hyperion Therapeutics, based in San Francisco.
 

More Information

Copyright © 2013 HealthDay. All rights reserved.
 
 

Most Popular

Recommended Reading

The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the US Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, including the kidneys.
Treating patients with migraines and psychiatric comorbidities can require a delicate balancing act of medications and other forms of therapy.
In many cases helping patients manage their migraine headaches can prove to be enough of a challenge. Adding psychiatric conditions to the diagnosis can further complicate the treatment process for doctors.
Patients with exocrine pancreatic insufficiency treated with pancreatin for up to one year experienced improvements in gastrointestinal symptoms and reduction in the severity of their recurrent pain.
$vAR$